Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study.
J Alzheimers Dis. 2019 Apr 1. doi: 10.3233/JAD-181148.
Jernerén F1, Cederholm T2,3, Refsum H4,5, Smith AD5, Turner C5, Palmblad J6, Eriksdotter M3,7, Hjorth E7, Faxen-Irving G7, Wahlund LO7, Schultzberg M7, Basun H2, Freund-Levi Y7,8,9,10.
Items in both categories Omega-3 and Cognitive are listed here:
- Omega-3 helps brains of seniors – May 2019
- Omega-3 helped Alzheimer’s only if good level of B vitamins – RCT April 2019
- Standard Omega-3 not get past BB barrier in seniors at high risk of Alzheimer’s – Patrick hypothesis Oct 2018
- APOE4 gene problems (Alzheimer’s) reduced by both Vitamin D and Omega-3 - Dec 2018
- Omega-3 is important for Brain Health during all phases of life – Aug 2018
- Hypothesis: Omega-3 reduces Alzheimer’s directly and via the gut – Sept 2018
- Improve Cognitive Health and Memory with Vitamin D and Omega-3 – World Patent March 2018
- IQ levels around the world are falling (perhaps lower Vitamin D, Iodine, or Omega-3)
- Adding Vitamin D, Omega-3, etc to children’s milk improved memory (yet again) – RCT June 2018
- Omega-3, Vitamin D, Folic acid etc. during pregnancy and subsequent mental illness of child – March 2018
- Why Alzheimer’s studies using Omega-3 have mixed results – quality, dose size, Omega-6, genes, etc. March 2018
- Benefits of Omega-3 beyond heart health - LEF Feb 2018
- Supplementation while pregnant and psychotic – 20 percent Omega-3, 6 percent Vitamin D – June 2016
- ADHD, Autism, Early Psychosis and Omega-3 – review Dec 2017
- Mild Traumatic Brain Injury prevented with Omega-3, Resveratrol, etc (in rats) – Oct 2017
- Omega-3 found to treat Alzheimer’s and Parkinson’s in animals – Sept 2017
- Do You Believe the Myth That You Can't Prevent Alzheimer's – Mercola, Aug 2017
- Violent schizophrenia patients treated by 3 months of Omega-3 – RCT Aug 2017
- Psychosis risk reduced for 80 weeks by just 12 weeks of Omega-3 – RCT Aug 2017
- Alzheimer’s (apoE4) may require more than Omega-3 - May 2017
- Infants getting 1 g of Omega-3 for 12 weeks got better brains – RCT March 2017
- Omega-3 reduces many psychiatric disorders – 2 reviews 2016
- Cognitive Impairment 1.8 times more likely if low Omega-3– Oct 2016
- Omega-3 may treat schizophrenia
- Benefits of Omega-3 on brain development
- Omega-3 helps childhood cognition – meta-analysis April 2016
- Football Brain injuries prevented by Omega-3 – RCT Jan 2016
- Schizophrenia treated by 6 months of Omega-3 – RCT Nov 2015
- Omega-3 and infant development - dissertation Sept 2015
- Omega-3 etc improved both cognition and mobility of older women – Aug 2015
- Schizophrenia relapses reduced 3X by Omega-3 – RCT Mar 2015
- Cognitive decline in elderly slowed by Omega-3 – meta-analysis May 2015
- Cognitively impaired brain atrophy was slowed 40 percent by Omega-3 and B vitamins – RCT July 2015
- Omega-3, Vitamin D, and other nutrients decrease mental health problems – March 2015
- Vitamin D, Omega-3 supplementation helps cognition – perhaps due to serotonin – Feb 2015
- Vitamin D and Omega-3 may reduce cortical atrophy with age – Nov 2013
- Alzheimer’s and Vitamins D, B, C, E, as well as Omega-3, metals, etc. – June 2013
- Spinal cord problems more likely if TBI if little Omega-3 in diet – June 2013
- Traumatic brain injury treated by Vitamin D Progesterone Omega-3 and glutamine – May 2013
Trials of supplementation with omega-3 fatty acids (ω3-FAs) in patients with mild cognitive impairment or Alzheimer's disease (AD) have given inconsistent effects on cognitive decline. There is evidence of an interaction between B vitamin status and ω3-FAs in relation to brain atrophy and cognitive decline.
We investigated whether baseline levels of plasma total homocysteine (tHcy), a marker of B vitamin status, modify the effects of ω3-FAs supplementation on cognitive performance in moderate AD.
This post hoc analysis of the OmegAD trial included 171 community-based patients with AD (MMSE≥15): 88 patients received daily doses of 1.7 g docosahexaenoic acid and 0.6 g eicosapentaenoic acid for 6 months. Treatment outcome on cognition was analyzed according to baseline levels of tHcy using a general linear model and ANCOVA.
We found significant interactions between ω3-FA supplementation and tHcy on cognition and clinical stage assessed by
- MMSE (p = 0.040), global
- CDR (p = 0.059), and
- CDRsob (p = 0.023),
but not on ADAS-cog (p = 0.649). In patients with tHcy levels <11.7μmol/L, ω3-FA supplementation improved cognitive performance as measured by MMSE (+7.1%, 95% CI: 0.59 to 13.7%, p = 0.033) and clinical status as measured by CDRsob (-22.3%, 95% CI: -5.8 to -38.7%, p = 0.009) compared to placebo.
The effect of ω3-FA supplementation on MMSE and CDR appears to be influenced by baseline tHcy, suggesting that adequate B vitamin status is required to obtain beneficial effects of ω3-FA on cognition.